ERBB2 and chronic myelogenous leukemia, BCR-ABL1 positive: Currently, pharmacogenomic testing is used to predict clinical outcomes, e.g., CYP2C19 in patients taking clopidogrel, T315I mutation, which confers resistance to BCR-ABL inhibitors (imatinib, dasatinib, and nilotinib) in chronic myeloid leukemia, and ERBB2/HER2, which influences the resistance to trastuzumab.